 |
|
|
|
|
 |
Last Updated: Nov 2, 2013 - 11:52:55 AM |
Latest Research
:
Cancer
:
Blood
:
Multiple Myeloma
Predicting response of treatment in Multiple Myeloma patients
Researchers at Mayo Clinic Cancer Center, in cooperation with industry partners, have, for the first time, identified tumor specific alterations in the cellular pathway by which the multiple myeloma drug bortezomib (Velcade) works, and they have identified nine new genetic mutations in cancer cells that should increase a patient's chance of responding to the agent.The investigators say these findings, presented Sunday, Dec. 10, at the 2006 American Society of Hematology Annual Meeting in Orlando, may help physicians tailor treatment to patients with multiple myleoma, a difficult-to-treat cancer of plasma cells that is the second most common blood cancer in the United States.
Dec 10, 2006 - 12:50:40 PM
|
Latest Research
:
Cancer
:
Blood
:
Multiple Myeloma
Lenalidomide & dexamethasone combination shows promise for multiple myeloma treatment
Mayo Clinic Cancer Center investigators report that combination therapy with lenalidomide (RevlimidTM) and dexamethasone (combination is called Rev/Dex) looks like a breakthrough treatment for multiple myeloma. Results of a Phase II clinical trial were published online Aug. 23 in Blood.
Sep 4, 2005 - 7:16:00 AM
|
Latest Research
:
Cancer
:
Blood
:
Multiple Myeloma
Novel combination overcomes drug-resistant myeloma
A novel strategy devised by Dana-Farber Cancer Institute scientists has proved highly effective in killing drug-resistant multiple myeloma cells in the laboratory and could open a new form of attack on the deadly blood cancer, they report.
Jun 3, 2005 - 4:51:00 PM
|
Latest Research
:
Cancer
:
Blood
:
Multiple Myeloma
Bortezomib Based Therapies may Become the New Standard of Care in Multiple Myeloma
Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM - News) today announced the presentation of positive clinical results for VELCADE in treating patients across the multiple myeloma (MM) treatment paradigm at the 10th Annual International Myeloma Workshop (IMW) in Sydney, Australia. Data regarding the use of VELCADE as a single agent and in combination with standard and emerging MM therapies were reported at the meeting.
Apr 14, 2005 - 8:57:00 PM
|
Latest Research
:
Cancer
:
Blood
:
Multiple Myeloma
FDA Fully Approves Bortezomib for Treatment of Relapsed and Refractory Multiple Myeloma
Millennium Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) approved the Company's supplemental New Drug Application (sNDA) for VELCADE(Bortezomib). This approval expands the label to include the treatment of patients with multiple myeloma (MM) who have received at least one prior therapy.
Mar 26, 2005 - 10:02:00 AM
|
<< prev
next >>
|
|
|
|
| Health |
Gathering information about food is not top priority for individuals with high metabolisms
|
NIH renews funding for University of Maryland vaccine research
|
DHA-enriched formula in infancy linked to positive cognitive outcomes in childhood
|
New IOM report lays out plan to determine effectiveness of obesity prevention efforts
|
Vitamin D supplementation may delay precocious puberty in girls
|
Study: Pedometer program helps motivate participants to sit less, move more
|
Fish oil may stall effects of junk food on brain
|
Intake of low energy dense food better than skipping meals
|
Inaugural IOF Olof Johnell Science Award presented to Professor Harry Genant
|
Molecular hub links obesity, heart disease to high blood pressure
|
| | Healthcare |
Healthcare experts from UK and India meet at the UK Parliament to discuss ways to improve health care in India, UK
|
Flu pandemic infected one in five
|
Stigma preventing leprosy-cured from getting jobs
|
Measles, Mumps make a comeback in US
|
Melinda Gates calls on Akhilesh Yadav
|
'Movies, TV impact tobacco users more than newspapers'
|
Rockland to open three new hospitals in NCR
|
Spice Global enters healthcare business with hospital in Delhi
|
Delhi to expedite recruitment of doctors
|
India adds spice to US life, keeps it healthy
|
| | Latest Research |
How do consumers see a product when they hear music?
|
Drug activates virus against cancer
|
Bone loss associated with increased production of ROS
|
Sound preconditioning prevents ototoxic drug-induced hearing loss in mice
|
Crystal methamphetamine use by street youth increases risk of injecting drugs
|
Johns Hopkins-led study shows increased life expectancy among family caregivers
|
Moderate to severe psoriasis linked to chronic kidney disease, say experts
|
Licensing deal marks coming of age for University of Washington, University of Alabama-Birmingham
|
Simple blood or urine test to identify blinding disease
|
Physician job satisfaction driven by quality of patient care
|
| | Medical News |
NHRC issues notice to Kerala over infant deaths
|
Advanced breast cancer detecting machine comes to India
|
'Dispel myths about vitiligo'
|
NHRC summons Odisha chief secretary
|
Woman dies of swine flu in UP
|
Maharashtra, GE to modernise rural health care
|
Hypertension: India's silent killer
|
Need cautious effort to eradicate polio: Experts
|
Ayurveda experts develop online personalised health regimen
|
Soon a detailed study on 'diabesity': Doctors
|
| | Special Topics |
MPs express anguish at Delhi gang-rape, Shinde assures fast trial
|
Worrying rise in number of medical students in prostitution over last 10 years
|
Behold India's unfolding democratic revolution
|
Chinese woman cuts open her belly to save surgery cost
|
Improved Sense of Smell Produced Smarter Mammals
|
Two-year-old world's first to have extra DNA strand
|
172,155 kidney stones removed from one patient!
|
'Primodial Soup' theory for origin of life rejected in paper
|
Human species could have killed Neanderthal man
|
History, geography also seem to shape our genome
|
|
|
